Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
about
Combination versus sequential single agent chemotherapy for metastatic breast cancerDifferent dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapyDifferent dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapySystemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelinesDocetaxel/anthracycline combinations for breast cancer treatmentCHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancerCancer drug related cardiotoxicity during breast cancer treatment.Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy.First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy.Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials.The Role of Combination Chemotherapy in the Treatment of Patients with Metastatic Breast Cancer.Treatment for liver metastases from breast cancer: results and prognostic factors.Docetaxel in the treatment of breast cancer: current experience and future prospects.Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population.Prognosis in women with breast cancer and private extra insurance coverage.Optimal use of taxanes in metastatic breast cancerA phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients.International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.Gemcitabine single or combination chemotherapy in post anthracycline and taxane salvage treatment of metastatic breast cancer: retrospective analysis of 124 patients.Defining the optimal sequence for the systemic treatment of metastatic breast cancer.A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines.Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement.Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives.Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies.Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.Development of a new G-CSF product based on biosimilarity assessment.Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials.Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice.Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy.Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients.
P2860
Q24201726-68473052-F03C-48E1-9CFA-3F586B604FB6Q24240568-6664C438-06D6-45F6-9630-A598A2F2C257Q24243810-477F2922-4825-462B-937A-B11C5B0F96D0Q28080469-772B81E7-F810-4EBF-890C-FC522AB36E1BQ28288899-A3EBBC9B-D1BC-4C07-A18A-CA44CE8D531FQ28473504-4AB5173F-0289-4A67-AE1C-757FF5A26734Q30251498-F6FBF200-EA6C-40CF-8A18-F47DCB5272D0Q33395356-19C5B436-B0D6-4CA9-8014-536CB1C38BF0Q33420907-F6BB8C88-012F-4A16-AE0D-038EF265858DQ33785011-18C3E348-C982-4848-AC1A-B14BA43C9465Q34140051-44900B92-0AEA-4E4B-B651-2C94F87C420BQ35045527-7A11D9A2-324D-48F7-B661-26988824C6FDQ36235546-1D47E382-5689-4819-8A76-F7E363FF3A36Q36304283-92C7194C-C8D6-4C0C-BC56-8D9A9BD15215Q37067973-05880B19-6346-4F38-A635-FA8477F63EE8Q37225780-EF843789-8CD0-4935-8C96-33E5C2162D20Q37320677-53A58EC4-CD0E-4052-B9AD-8124E2700F60Q37329165-06566103-C4B5-424E-ADFD-83EB039F0E6FQ37341664-ED9B1C01-D61A-4CCB-ABF4-568BE42773E2Q37588645-536F2DFF-1D48-4ACB-976F-DBC3229A5FE9Q38092916-AF2FE116-8EE1-4706-B9B5-0E162654A311Q38608267-9CFCA61A-8278-4581-A4FA-FDBAEC6DB83FQ38682028-63D353DD-714F-420A-ABFA-2B4A01865B2CQ38854876-FAA11EEE-9459-4A6F-9A62-B01F9923D4C3Q39262493-8BCDBA30-C029-495F-B850-D524AF339FA0Q40889689-892A2A05-0D0E-4BBB-B43F-CC34E9874080Q40907746-C6F06502-DC45-4F95-8371-B78DF15365A6Q42643304-BEFA05EE-DBEB-4839-8AC9-A75FEAFB4E80Q46817262-E66ED510-45CE-45D1-A9BF-0B15AA932E56Q47222469-DFC9431B-0E06-4E96-B9E2-0657FB215C0FQ47867377-E5B8265D-A13A-42F2-BF38-C709B81C3943Q50061323-73047DC8-9F57-48E7-8C04-143E48CAE1D6Q50112937-732853E1-EF8D-48D5-B7A1-72F0B092526DQ53172587-B19DCC27-22BE-493F-AD43-0FF65C1D7E23Q53792224-A1491439-4C48-45FE-A40B-CAE85D868E36
P2860
Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Multicenter randomized trial c ...... (GEICAM-9903) phase III study.
@en
type
label
Multicenter randomized trial c ...... (GEICAM-9903) phase III study.
@en
prefLabel
Multicenter randomized trial c ...... (GEICAM-9903) phase III study.
@en
P2093
P356
P1476
Multicenter randomized trial c ...... (GEICAM-9903) phase III study
@en
P2093
Agustí Barnadas
Antonio Casado
Carlos Jara
Emilio Alba
Encarna Adrover
Manuel Ramos
Margarita Amenedo
Pedro Sánchez-Rovira
Spanish Breast Cancer Research Group
P304
P356
10.1200/JCO.2004.08.125
P407
P577
2004-07-01T00:00:00Z